Latest Memphasys (ASX:MEM) News

Memphasys has cleared a key regulatory hurdle in Vietnam for its Felix™ System, prompting a significant first commercial cartridge order and marking early clinical success in a fast-growing fertility market.

Wellnex led the healthcare market after agreeing to sell Pain Away for up to A$21.3 million. Neuren and Lumos also rose strongly as sales, royalties and product orders improved.

Memphasys secures exclusive Felix™ commercialisation agreement in Poland, marking its third European market entry with a two-year contract valued at approximately A$350,000.

Wild swings hit the ASX this week, with Janus Electric doubling, Aura sliding almost 30%, and TechGen jumping more than 22%. Big news kept landing, but many stocks still fell as early gains faded and traders locked in profits.

Big price swings hit healthcare stocks this week, but the sharpest falls did not always match the news flow. Revenue growth, trial progress and fresh US deals kept buying interest alive across parts of the sector.

Memphasys delivered a record $150,000 quarterly revenue, secured its largest Felix™ supply contract with Monash IVF, and expanded into UK and Southeast Asian IVF markets, positioning for accelerated growth in FY27.

Cann Group, OncoSil and Imugene led a busy healthcare week as investors chased FDA steps, cancer trial news and balance-sheet fixes. Elsewhere, revenue growth, hospital contracts and fresh funding kept money flowing into names with near-term commercial milestones.

Memphasys has locked in a three-year exclusive distribution agreement for its Felix™ sperm separation system in Thailand, targeting a key IVF market with 110 clinics and 20,000–30,000 cycles annually. The deal adds approximately A$430,500 in contracted revenue, lifting South-East Asian minimum contracts to about A$1 million and contributing to FY2026 Felix™ sales now exceeding A$3 million.

AI cardiology, cancer research and pharma expansion drove the biggest moves in healthcare stocks this week. Investors paid up for fresh funding and regulatory wins, while some raisings and weak trading updates kept pressure on others.

Memphasys has rapidly established a foothold in the UK IVF market, securing four active commercial trials and initial orders for its Felix™ sperm selection system within weeks of launch. This momentum aligns with its global expansion strategy targeting major fertility markets.

Healthcare stocks split into two camps this week: names with fresh data or contracts found buyers, while capital raisings and trial shock sent others sharply lower. The biggest move came from Cynata’s return to trade, but steady progress in Alzheimer’s, oncology, diagnostics and aged care software also kept the sector busy.

Memphasys has secured $1.2 million through a share placement to support the global expansion and manufacturing scale-up of its Felix™ sperm selection system. The company also extended a major convertible note, reinforcing financial flexibility amid growing international contracts.